Jia-Long Fang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Jia-Long Fang has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Frederick A. Beland
Division of Biochemical Toxicology, National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR 72079, USA
15 shared publications Frederick A. Beland
Division of Biochemical Toxicology, National Center for Toxicological Research (NCTR), U.S. Food and Drug Administration, Jefferson, USA
8 shared publicationsYuanfeng Wu
Division of Biochemical Toxicology, National Center for Toxicological Research (NCTR), U.S Food and Drug Administration, 3900 NCTR Road, Jefferson, AR, 72079, USA
7 shared publicationsGonçalo Gamboa da Costa
Division of Biochemical Toxicology, National Center for Toxicological Research, Jefferson, Arkansas 72079, U.S.A.
5 shared publicationsSi Chen
Division of Biochemical Toxicology, National Center for Toxicological Research (NCTR), U.S. Food and Drug Administration, Jefferson, USA
5 shared publicationsGreg R. Olson
Toxicologic Pathology Associates, Inc., National Center for Toxicological Research, Jefferson, USA
4 shared publications
Latest Publications
- Open Access
- 15 July 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Contribution of cytochrome P450-mediated metabolism to clavulanic acid-induced cytotoxicity in TK6-derived cytochrome P450-overexpressing cell lines
Clavulanic acid, a β-lactamase inhibitor, is widely co-administered with amoxicillin (as in Augmentin ) to treat a broad range of mild-to-moderate bacterial infections by inhibiting β-lactamase enzymes produced by resistant bacterial strains. Despite its therapeutic efficacy, clavulanic acid has been associated with drug-induced liver injury, but the underlying mechanisms for this toxicity remain poorly understood. We investigated the contribution of cytochrome P450 (CYP)-mediated metabolism in relation to clavulanic acid-induced cytotoxicity. A panel of TK6-derived cell lines overexpressing 18 individual CYP isoforms (CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2A7, CYP2A13, CYP2B6, CYP2C8, CYP2C9, CYP2C18, CYP2C19, CYP2D6, CYP2E1, CYP3A4, CYP3A5, CYP3A7, CYP4A11, and CYP4B1) was employed. Cells were incubated for 24 and 48 h with freshly prepared clavulanic acid (20-1000 µM) in RPMI-1640 medium, and the half-maximal inhibitory concentration (IC₅₀) was determined. Cell growth was more markedly delayed after 48 h of treatment than after 24 h of exposure. Following 48 h of treatment, 13 CYP-overexpressing cell lines showed reduced IC₅₀ values compared with parental TK6 and TK6/vector control cells. The rank order was CYP3A4 ≈ CYP3A7 ≈ CYP1A1 < CYP4A11 ≈ CYP2A13 ≈ CYP2C19 < CYP2B6 ≈ CYP1A2 ≈ CYP2C9 < CYP1B1 ≈ CYP2D6 < CYP2E1 ≈ CYP2C18, with the greatest decrease (~2-fold) observed in TK6/CYP3A4 cells. In contrast, five isoforms (CYP2A6, CYP2A7, CYP2C8, CYP3A5, and CYP4B1) showed IC₅₀ values comparable to controls. To examine further the cytotoxic response, TK6/CYP vector and TK6/CYP3A4 cells were treated for 48 h with equitoxic concentrations of clavulanic acid (0.1×, 0.5×, and 1.0× IC₅₀). The exposures resulted in a significant concentration-dependent reduction in cell viability, accompanied by increased lactate dehydrogenase release, the induction of apoptosis, G₀/G₁ phase arrest, and a concentration-dependent elevation in γH2AX phosphorylation, indicative of DNA damage. In conclusion, CYP enzymes, especially CYP3A4, likely contribute to clavulanate-induced cytotoxicity, with necrosis, cell cycle disruption, and γH2AX-associated apoptosis as key cellular responses.
- 15 July 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessContribution of cytochrome P450-mediated metabolism to clavulanic acid-induced cytotoxicity in TK6-derived cytochrome P450-overexpressing cell lines
Clavulanic acid, a β-lactamase inhibitor, is widely co-administered with amoxicillin (as in Augmentin ) to treat a broad range of mild-to-moderate bacterial infections by inhibiting β-lactamase enzymes produced by resistant bacterial strains. Despite its therapeutic efficacy, clavulanic acid has been associated with drug-induced liver injury, but the underlying mechanisms for this toxicity remain poorly understood. We investigated the contribution of cytochrome P450 (CYP)-mediated metabolism in relation to clavulanic acid-induced cytotoxicity. A panel of TK6-derived cell lines overexpressing 18 individual CYP isoforms (CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2A7, CYP2A13, CYP2B6, CYP2C8, CYP2C9, CYP2C18, CYP2C19, CYP2D6, CYP2E1, CYP3A4, CYP3A5, CYP3A7, CYP4A11, and CYP4B1) was employed. Cells were incubated for 24 and 48 h with freshly prepared clavulanic acid (20-1000 µM) in RPMI-1640 medium, and the half-maximal inhibitory concentration (IC₅₀) was determined. Cell growth was more markedly delayed after 48 h of treatment than after 24 h of exposure. Following 48 h of treatment, 13 CYP-overexpressing cell lines showed reduced IC₅₀ values compared with parental TK6 and TK6/vector control cells. The rank order was CYP3A4 ≈ CYP3A7 ≈ CYP1A1 < CYP4A11 ≈ CYP2A13 ≈ CYP2C19 < CYP2B6 ≈ CYP1A2 ≈ CYP2C9 < CYP1B1 ≈ CYP2D6 < CYP2E1 ≈ CYP2C18, with the greatest decrease (~2-fold) observed in TK6/CYP3A4 cells. In contrast, five isoforms (CYP2A6, CYP2A7, CYP2C8, CYP3A5, and CYP4B1) showed IC₅₀ values comparable to controls. To examine further the cytotoxic response, TK6/CYP vector and TK6/CYP3A4 cells were treated for 48 h with equitoxic concentrations of clavulanic acid (0.1×, 0.5×, and 1.0× IC₅₀). The exposures resulted in a significant concentration-dependent reduction in cell viability, accompanied by increased lactate dehydrogenase release, the induction of apoptosis, G₀/G₁ phase arrest, and a concentration-dependent elevation in γH2AX phosphorylation, indicative of DNA damage. In conclusion, CYP enzymes, especially CYP3A4, likely contribute to clavulanate-induced cytotoxicity, with necrosis, cell cycle disruption, and γH2AX-associated apoptosis as key cellular responses.
- Open Access
- 25 March 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-13
Flow cytometric analysis of the SARS coronavirus 2 antibodies in human plasma
COVID-19 is an infectious disease caused by the severe acute respiratory syndrome coronavirus (SARS-CoV-2). Anti-SARS-CoV-2 antibodies can provide information on patient immunity, identify asymptomatic patients, and track the spread of COVID-19. Efforts have been made to develop methods to detect anti-SARS-CoV-2 antibodies in humans. Here, we describe a flow cytometric assay for the simultaneous detection of anti-SARS-CoV-2 IgG and IgM in human plasma. To assess the antibody response against the different SARS-CoV-2 structural proteins, five viral recombinant proteins, including spike protein subunit 1 (S1), N-terminal domain of S1 (S1A), spike receptor-binding domain (RBD), spike protein subunit 2 (S2), and nucleocapsid protein (N), were generated. A comparison of the antibody profiles detected by the assay with plasma from 100 healthy blood donors collected prior to the COVID-19 pandemic and plasma from 100 virologically confirmed COVID-19 patients demonstrated a clear discrimination between the two groups. Among the COVID-19 patients, the antibody responses for the viral proteins, as determined by their prevalence, were anti-RBD IgG = anti-N IgG > anti-S1 IgG > anti-S1A IgG > anti-S2 IgG, and anti-RBD IgM > anti-S1 IgM > anti-N IgM > anti-S2 IgM. The prevalence of anti-SARS-CoV-2 IgG and IgM was not associated with sex, age, race, days after the onset of symptoms, or severity of illness, except for a higher prevalence of anti-S2 IgG being observed in men than in women. The levels of anti-RBD IgG were higher in patients 65 years and older and in patients who had severe symptoms. Similarly, patients who had severe symptoms exhibited higher levels of anti-S1 and anti-S1A IgG than patients who had mild or moderate symptoms. The levels of anti-RBD IgM tended to be higher in men but did not differ among age, race, days after the onset of symptoms, or severity of illness. Our study indicates that the flow cytometric assay, especially using RBD as target antigen, can be used to detect simultaneously anti-SARS-CoV-2 IgG and IgM antibodies in human plasma.
- 25 March 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-13
Open AccessFlow cytometric analysis of the SARS coronavirus 2 antibodies in human plasma
COVID-19 is an infectious disease caused by the severe acute respiratory syndrome coronavirus (SARS-CoV-2). Anti-SARS-CoV-2 antibodies can provide information on patient immunity, identify asymptomatic patients, and track the spread of COVID-19. Efforts have been made to develop methods to detect anti-SARS-CoV-2 antibodies in humans. Here, we describe a flow cytometric assay for the simultaneous detection of anti-SARS-CoV-2 IgG and IgM in human plasma. To assess the antibody response against the different SARS-CoV-2 structural proteins, five viral recombinant proteins, including spike protein subunit 1 (S1), N-terminal domain of S1 (S1A), spike receptor-binding domain (RBD), spike protein subunit 2 (S2), and nucleocapsid protein (N), were generated. A comparison of the antibody profiles detected by the assay with plasma from 100 healthy blood donors collected prior to the COVID-19 pandemic and plasma from 100 virologically confirmed COVID-19 patients demonstrated a clear discrimination between the two groups. Among the COVID-19 patients, the antibody responses for the viral proteins, as determined by their prevalence, were anti-RBD IgG = anti-N IgG > anti-S1 IgG > anti-S1A IgG > anti-S2 IgG, and anti-RBD IgM > anti-S1 IgM > anti-N IgM > anti-S2 IgM. The prevalence of anti-SARS-CoV-2 IgG and IgM was not associated with sex, age, race, days after the onset of symptoms, or severity of illness, except for a higher prevalence of anti-S2 IgG being observed in men than in women. The levels of anti-RBD IgG were higher in patients 65 years and older and in patients who had severe symptoms. Similarly, patients who had severe symptoms exhibited higher levels of anti-S1 and anti-S1A IgG than patients who had mild or moderate symptoms. The levels of anti-RBD IgM tended to be higher in men but did not differ among age, race, days after the onset of symptoms, or severity of illness. Our study indicates that the flow cytometric assay, especially using RBD as target antigen, can be used to detect simultaneously anti-SARS-CoV-2 IgG and IgM antibodies in human plasma.
- 24 October 2023
- Published by Springer Nature in Archives of Toxicology
- Vol. 98 (1) , 335-345
Two-year dermal carcinogenicity bioassay of triclosan in B6C3F1 mice
Triclosan is a widely used antimicrobial agent in personal care products, household items, medical devices, and clinical settings. Due to its extensive use, there is potential for humans in all age groups to receive lifetime exposures to triclosan, yet data on the chronic dermal toxicity/carcinogenicity of triclosan are still lacking. We evaluated the toxicity/carcinogenicity of triclosan administered dermally to B6C3F1 mice for 104 weeks. Groups of 48 male and 48 female B6C3F1 mice received dermal applications of 0, 1.25, 2.7, 5.8, or 12.5 mg triclosan/kg body weight (bw)/day in 95% ethanol, 7 days/week for 104 weeks. Vehicle control animals received 95% ethanol only; untreated, naïve control mice did not receive any treatment. There were no significant differences in survival among the groups. The highest dose of triclosan significantly decreased the body weight of mice in both sexes, but the decrease was ≤ 9%. Minimal-to-mild epidermal hyperplasia, suppurative inflammation (males only), and ulceration (males only) were observed at the application site in the treated groups, with the highest incidence occurring in the 12.5 mg triclosan/kg bw/day group. No tumors were identified at the application site. Female mice had a positive trend in the incidence of pancreatic islet adenoma. In male mice, there were positive trends in the incidences of hepatocellular carcinoma and hepatocellular adenoma or carcinoma (combined), with the increase of carcinoma being significant in the 5.8 and 12.5 mg/kg/day groups and the increase in hepatocellular adenoma or carcinoma (combined) being significant in the 2.7, 5.8, and 12.5 mg/kg/day groups.
- 24 October 2023
- Published by Springer Nature in Archives of Toxicology
- Vol. 98 (1) , 335-345
Two-year dermal carcinogenicity bioassay of triclosan in B6C3F1 mice
Triclosan is a widely used antimicrobial agent in personal care products, household items, medical devices, and clinical settings. Due to its extensive use, there is potential for humans in all age groups to receive lifetime exposures to triclosan, yet data on the chronic dermal toxicity/carcinogenicity of triclosan are still lacking. We evaluated the toxicity/carcinogenicity of triclosan administered dermally to B6C3F1 mice for 104 weeks. Groups of 48 male and 48 female B6C3F1 mice received dermal applications of 0, 1.25, 2.7, 5.8, or 12.5 mg triclosan/kg body weight (bw)/day in 95% ethanol, 7 days/week for 104 weeks. Vehicle control animals received 95% ethanol only; untreated, naïve control mice did not receive any treatment. There were no significant differences in survival among the groups. The highest dose of triclosan significantly decreased the body weight of mice in both sexes, but the decrease was ≤ 9%. Minimal-to-mild epidermal hyperplasia, suppurative inflammation (males only), and ulceration (males only) were observed at the application site in the treated groups, with the highest incidence occurring in the 12.5 mg triclosan/kg bw/day group. No tumors were identified at the application site. Female mice had a positive trend in the incidence of pancreatic islet adenoma. In male mice, there were positive trends in the incidences of hepatocellular carcinoma and hepatocellular adenoma or carcinoma (combined), with the increase of carcinoma being significant in the 5.8 and 12.5 mg/kg/day groups and the increase in hepatocellular adenoma or carcinoma (combined) being significant in the 2.7, 5.8, and 12.5 mg/kg/day groups.
- 29 January 2022
- Published by Elsevier in Toxicology Letters
- Vol. 359, 22-30
Toxicity of high-molecular-weight polyethylene glycols in Sprague Dawley rats
- 29 January 2022
- Published by Elsevier in Toxicology Letters
- Vol. 359, 22-30
Toxicity of high-molecular-weight polyethylene glycols in Sprague Dawley rats
- Open Access
- 1 January 2021
- Published by Elsevier in Toxicology Reports
- Vol. 8, 148-154
Flow cytometry analysis of anti-polyethylene glycol antibodies in human plasma
- 1 January 2021
- Published by Elsevier in Toxicology Reports
- Vol. 8, 148-154
Open AccessFlow cytometry analysis of anti-polyethylene glycol antibodies in human plasma
- 1 February 2020
- Published by Elsevier in Toxicology in Vitro
- Vol. 62, 104669
Apoptosis contributes to the cytotoxicity induced by amodiaquine and its major metabolite N-desethylamodiaquine in hepatic cells
- 1 February 2020
- Published by Elsevier in Toxicology in Vitro
- Vol. 62, 104669
Apoptosis contributes to the cytotoxicity induced by amodiaquine and its major metabolite N-desethylamodiaquine in hepatic cells
- 20 September 2018
- Published by Springer Nature in Archives of Toxicology
- Vol. 92 (11) , 3391-3402
Role of peroxisome proliferator-activated receptor alpha (PPARα) and PPARα-mediated species differences in triclosan-induced liver toxicity
Triclosan, a widely used broad spectrum anti-bacterial agent, is hepatotoxic in rodents and exhibits differential effects on mouse and human peroxisome proliferator-activated receptor alpha (PPARα) in vitro; however, the mechanism underlying triclosan-induced liver toxicity has not been elucidated. This study examined the role of mouse and human PPARα in triclosan-induced liver toxicity by comparing the effects between wild-type and PPARα-humanized mice. Female mice of each genotype received dermal applications of 0, 58, or 125 mg triclosan/kg body weight daily for 13 weeks. Following the treatment, triclosan caused an increase in liver weight and relative liver weight only in wild-type mice. The expression levels of PPARα target genes cytochrome P450 4A and acyl-coenzyme A oxidase 1 were increased in livers of both wild-type and PPARα-humanized mice, indicating that triclosan activated PPARα. Triclosan also elevated the expression levels of peroxisomal membrane protein PMP70 and catalase in the livers of both genotypes, suggesting that triclosan promoted the production of hepatocyte peroxisomes. There was an enhanced expression of cyclin D1, c-myc, proliferating cell nuclear antigen, and Ki67, and a higher percentage of BrdU-labeled hepatocytes in wild-type mice, but not in PPARα-humanized mice, demonstrating triclosan-activated PPARα had differential effects on the hepatocyte proliferation. These findings imply that the differential effects of triclosan-activated PPARα on cell proliferation may play a role in the species differences in triclosan-induced liver toxicity.
- 20 September 2018
- Published by Springer Nature in Archives of Toxicology
- Vol. 92 (11) , 3391-3402
Role of peroxisome proliferator-activated receptor alpha (PPARα) and PPARα-mediated species differences in triclosan-induced liver toxicity
Triclosan, a widely used broad spectrum anti-bacterial agent, is hepatotoxic in rodents and exhibits differential effects on mouse and human peroxisome proliferator-activated receptor alpha (PPARα) in vitro; however, the mechanism underlying triclosan-induced liver toxicity has not been elucidated. This study examined the role of mouse and human PPARα in triclosan-induced liver toxicity by comparing the effects between wild-type and PPARα-humanized mice. Female mice of each genotype received dermal applications of 0, 58, or 125 mg triclosan/kg body weight daily for 13 weeks. Following the treatment, triclosan caused an increase in liver weight and relative liver weight only in wild-type mice. The expression levels of PPARα target genes cytochrome P450 4A and acyl-coenzyme A oxidase 1 were increased in livers of both wild-type and PPARα-humanized mice, indicating that triclosan activated PPARα. Triclosan also elevated the expression levels of peroxisomal membrane protein PMP70 and catalase in the livers of both genotypes, suggesting that triclosan promoted the production of hepatocyte peroxisomes. There was an enhanced expression of cyclin D1, c-myc, proliferating cell nuclear antigen, and Ki67, and a higher percentage of BrdU-labeled hepatocytes in wild-type mice, but not in PPARα-humanized mice, demonstrating triclosan-activated PPARα had differential effects on the hepatocyte proliferation. These findings imply that the differential effects of triclosan-activated PPARα on cell proliferation may play a role in the species differences in triclosan-induced liver toxicity.
- 18 July 2018
- Published by Elsevier in Biochemical Pharmacology
- Vol. 155, 455-467
Effects of human sulfotransferases on the cytotoxicity of 12-hydroxynevirapine
- 18 July 2018
- Published by Elsevier in Biochemical Pharmacology
- Vol. 155, 455-467
Effects of human sulfotransferases on the cytotoxicity of 12-hydroxynevirapine
- 28 November 2016
- Published by Springer Nature in Archives of Toxicology
- Vol. 91 (6) , 2405-2423
Cytochrome P450-mediated metabolism of triclosan attenuates its cytotoxicity in hepatic cells
Triclosan is a widely used broad-spectrum anti-bacterial agent. The objectives of this study were to identify which cytochrome P450 (CYP) isoforms metabolize triclosan and to examine the effects of CYP-mediated metabolism on triclosan-induced cytotoxicity. A panel of HepG2-derived cell lines was established, each of which overexpressed a single CYP isoform, including CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2A7, CYP2A13, CYP2B6, CYP2C8, CYP2C9, CYP2C18, CYP2C19, CYP2D6, CYP2E1, CYP3A4, CYP3A5, CYP3A7, CYP4A11, and CYP4B1. The extent of triclosan metabolism by each CYP was assessed by reversed-phase high-performance liquid chromatography with online radiochemical detection. Seven isoforms were capable of metabolizing triclosan, with the order of activity being CYP1A2 > CYP2B6 > CYP2C19 > CYP2D6 ≈ CYP1B1 > CYP2C18 ≈ CYP1A1. The remaining 11 isoforms (CYP2A6, CYP2A7, CYP2A13, CYP2C8, CYP2C9, CYP2E1, CYP3A4, CYP3A5, CYP3A7, CYP4A11, and CYP4B1) had little or no activity toward triclosan. Three metabolites were detected: 2,4-dichlorophenol, 4-chlorocatechol, and 5′-hydroxytriclosan. Consistent with the in vitro screening data, triclosan was extensively metabolized in HepG2 cells overexpressing CYP1A2, CYP2B6, CYP2C19, CYP2D6, and CYP2C18, and these cells were much more resistant to triclosan-induced cytotoxicity compared to vector cells, suggesting that CYP-mediated metabolism of triclosan attenuated its cytotoxicity. In addition, 2,4-dichlorophenol and 4-chlorocatechol were less toxic than triclosan to HepG2/vector cells. Conjugation of triclosan, catalyzed by human glucuronosyltransferases (UGTs) and sulfotransferases (SULTs), also occurred in HepG2/CYP-overexpressing cells and primary human hepatocytes, with a greater extent of conjugation being associated with higher cell viability. Co-administration of triclosan with UGT or SULT inhibitors led to greater cytotoxicity in HepG2 cells and primary human hepatocytes, indicating that glucuronidation and sulfonation of triclosan are detoxification pathways. Among the 18 CYP-overexpressing cell lines, an inverse correlation was observed between cell viability and the level of triclosan in the culture medium. In conclusion, human CYP isoforms that metabolize triclosan were identified, and the metabolism of triclosan by CYPs, UGTs, and SULTs decreased its cytotoxicity in hepatic cells.
- 28 November 2016
- Published by Springer Nature in Archives of Toxicology
- Vol. 91 (6) , 2405-2423
Cytochrome P450-mediated metabolism of triclosan attenuates its cytotoxicity in hepatic cells
Triclosan is a widely used broad-spectrum anti-bacterial agent. The objectives of this study were to identify which cytochrome P450 (CYP) isoforms metabolize triclosan and to examine the effects of CYP-mediated metabolism on triclosan-induced cytotoxicity. A panel of HepG2-derived cell lines was established, each of which overexpressed a single CYP isoform, including CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2A7, CYP2A13, CYP2B6, CYP2C8, CYP2C9, CYP2C18, CYP2C19, CYP2D6, CYP2E1, CYP3A4, CYP3A5, CYP3A7, CYP4A11, and CYP4B1. The extent of triclosan metabolism by each CYP was assessed by reversed-phase high-performance liquid chromatography with online radiochemical detection. Seven isoforms were capable of metabolizing triclosan, with the order of activity being CYP1A2 > CYP2B6 > CYP2C19 > CYP2D6 ≈ CYP1B1 > CYP2C18 ≈ CYP1A1. The remaining 11 isoforms (CYP2A6, CYP2A7, CYP2A13, CYP2C8, CYP2C9, CYP2E1, CYP3A4, CYP3A5, CYP3A7, CYP4A11, and CYP4B1) had little or no activity toward triclosan. Three metabolites were detected: 2,4-dichlorophenol, 4-chlorocatechol, and 5′-hydroxytriclosan. Consistent with the in vitro screening data, triclosan was extensively metabolized in HepG2 cells overexpressing CYP1A2, CYP2B6, CYP2C19, CYP2D6, and CYP2C18, and these cells were much more resistant to triclosan-induced cytotoxicity compared to vector cells, suggesting that CYP-mediated metabolism of triclosan attenuated its cytotoxicity. In addition, 2,4-dichlorophenol and 4-chlorocatechol were less toxic than triclosan to HepG2/vector cells. Conjugation of triclosan, catalyzed by human glucuronosyltransferases (UGTs) and sulfotransferases (SULTs), also occurred in HepG2/CYP-overexpressing cells and primary human hepatocytes, with a greater extent of conjugation being associated with higher cell viability. Co-administration of triclosan with UGT or SULT inhibitors led to greater cytotoxicity in HepG2 cells and primary human hepatocytes, indicating that glucuronidation and sulfonation of triclosan are detoxification pathways. Among the 18 CYP-overexpressing cell lines, an inverse correlation was observed between cell viability and the level of triclosan in the culture medium. In conclusion, human CYP isoforms that metabolize triclosan were identified, and the metabolism of triclosan by CYPs, UGTs, and SULTs decreased its cytotoxicity in hepatic cells.